More Than 300 Companies Adopt Vault Quality Applications to Unify Global Quality Processes
Veeva Systems (NYSE: VEEV) today announced increasing numbers of biopharma, contract services, generics, and medical device and diagnostics companies are adopting Veeva Vault Quality Suite applications to unify and modernize quality management globally. More than 300 organizations, including 13 of the 20 largest global pharmaceutical companies, use Veeva applications for managing quality processes, content, and training. Veeva’s rapid pace of innovation is delivering the industry’s most advanced and comprehensive suite of applications on a single cloud platform to streamline global quality processes.
“Veeva’s quality applications work together seamlessly and deliver continuous innovation based on our needs,” said Lexie Pieper, vice president, quality assurance at Celularity, Inc. “Veeva Vault Quality Suite gives us a powerful set of solutions so our organization has complete visibility into quality information and processes. We can’t wait to see the quality innovations Veeva delivers next.”
There is a growing need among life sciences organizations to bring together disconnected systems and incorporate internal and external stakeholders into quality processes. Companies can transform end-to-end quality management with Vault Quality applications, increasing collaboration and visibility across the enterprise.
Veeva continues to deliver innovations that help customers streamline quality content and processes across global sites, suppliers, contract manufacturers, and other partners. In less than three years, Veeva’s suite of quality applications has expanded to help customers adapt and respond quickly to changing business requirements, including:
- Vault Training to simplify role-based qualifications and training;
- Integrated change control and variation management across quality and regulatory using Vault QMS and Veeva Vault Registrations, as well as quality risk management in Vault QMS to identify and mitigate risks proactively;
- Vault Station Manager, a mobile application that provides up-to-date content directly to operators on the manufacturing floor;
- And Vault Product Surveillance to enable medical device and diagnostics companies to simplify and standardize the post-market surveillance process globally.
“Modernizing and unifying quality management has become a top priority across life sciences,” said Mike Jovanis, vice president of Vault Quality. “Veeva Vault Quality Suite is helping customers streamline business processes, increase operational efficiency, and drive greater agility throughout the product life cycle.”
The Vault Quality Suite includes Vault QMS, Vault QualityDocs, Vault Training, Vault Station Manager, and Vault Product Surveillance to automate and harmonize quality processes globally. Vault Registrations is part of Veeva Vault RIM, a suite with applications used by 12 of the top 20 global pharmaceutical companies to streamline end-to-end global regulatory processes.
Learn more at the upcoming Veeva R&D and Quality Summit, October 13-14, 2020. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P5925.11.2020 12:13:00 CET | Press release
Celltrion Group today announced enrolment completion of 327 patients with mild-to-moderate symptoms of SARS-CoV-2 infection in the global Phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. Celltrion anticipates submission for emergency use authorisation (EUA) to the Korean Ministry of Food and Drug Safety (MFDS), conditional on results from the global Phase II pivotal trial. The global Phase II clinical trial is a randomised, double-blind, placebo-controlled and parallel-group trial designed to evaluate the efficacy and safety of CT-P59 in combination with standard of care in patients with SARS-CoV-2 infection. The trial enrolled 327 patients with mild-to-moderate symptoms of COVID-19 across three groups (placebo, low concentration, high concentration) and Celltrion is set to obtain the results for global Phase II trial. In addition, Celltrion plans to initiate a global Phase III clinical trial in more than 10 countries in order to obtain more
iHeartMedia and Podimo Partner to Translate and Adapt Widely Popular Podcasts For Listeners Globally25.11.2020 12:00:00 CET | Press release
iHeartMedia, the No. 1 audio company in America and the No. 1 podcast publisher globally, and European podcast platform Podimo today announced a strategic partnership to translate and adapt popular podcasts across the globe in different languages, introducing these podcasts to hundreds of millions of new listeners. The partnership will kick off with the widely popular true crime podcast “Forgotten: Women of Juárez” (Olvidadas: Muertes de Juárez) about femicides in Mexico’s most dangerous city in three languages: Spanish, German and Danish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005440/en/ In one of 2020’s most intimate and shocking true crime podcasts, “Forgotten: Women of Juárez,” from iHeartMedia and Unusual Productions, hosts Mónica Ortiz Uribe and Oz Woloshyn investigate theories surrounding the disappearance of hundreds of young women along the Mexican border city of Juárez. Some are tragically found with
RIDDLE&CODE Launches Trusted Gateway to Accelerate the Future of the Distributed Energy Market and Enable New Business Models25.11.2020 10:30:00 CET | Press release
The shift from the centralised energy system with a small number of dominant bulk producers to a decentralised renewable marketplace with a multiway flow of information requires not only new business models and entities but also a guarantee that the data generated out of them are trusted and immutable. RIDDLE&CODE laid the foundation for accelerating the future of decentralised energy by introducing the Trusted Gateway. At the core of the Trusted Gateway is the Secure Element, a part of RIDDLE&CODE’s “Built for Blockchain” product range, enabling the secure storage of the digital identity (private key) on any device through a combination of hardware and software. By providing secure public/private key infrastructure, the Trusted Gateway solves the problem of machine identity and creates a unique, cryptographically secured digital representation of an object, assigning it with identity, addressability and transaction capabilities. “In the context of the energy system, by giving the digi
BearingPoint: Organizations That Invest in Frontline Managerial Skills Are More Resilient and Adaptable Than Competitors25.11.2020 08:57:00 CET | Press release
The Covid-19 pandemic has shown that organizations that invest in frontline managerial skills are more resilient and adaptable than competitors. Frontline managers initiate process improvements and new ways of working. According to a recent study by the BearingPoint Institute, the research arm of management and technology consultancy BearingPoint, company leaders must make frontline managers a driving force for change to ensure transformation success and adapt to market changes. "With transformational pressures exerting themselves on business, frontline managers have never been more crucial to organizations. Our study shows how important it is to develop, empower and unleash the skills, enthusiasm, and innovation of these leaders. It is the only way to get the most out of digitalization and quickly adapt to the continuously changing market. Investing in frontline management will not only mean continuing success, but it will help you identify and hone tomorrow's leaders," says André Est
European Commission Approves Janssen’s TREMFYA ® ▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)25.11.2020 08:00:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved TREMFYA®▼ (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Guselkumab is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. It is already approved for the treatment of patients with moderate to severe plaque psoriasis. IL-23 is an important driver of the progression of inflammatory diseases including psoriasis and PsA, among others.1 PsA is a multifaceted, chronic, immune-mediated inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis
Universal Peace Federation: 70 Years After the Korean War World Leaders Call for Peace at Online Rally of Hope24.11.2020 19:19:00 CET | Press release
Millions of viewers tuned into hundreds of broadcast stations and gathered online to call for peace among and between nations at the third Rally of Hope sponsored by the Universal Peace Federation (UPF) in Korea on Sunday, Nov. 22. UPF was founded in 2005 by Rev. Dr. Sun Myung Moon and Dr. Hak Ja Han Moon and is an NGO in General Consultative Status with the United Nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005906/en/ Dr. Hak Ja Han Moon addresses live audience and online participants from all around the world at the Rally of Hope (Photo: Business Wire) Mrs. Moon announced two new projects: to set up Korean War memorials in those nations that do not yet have them and create an online registry of all those who sacrificed in any way to support Korea during its darkest hour. “All around the world, unforeseen and unexpected challenges are erupting in the realms of politics, economy and religion” she said. “We